Allergan Pulls FDA-Questioned Brochure
- Share via
IRVINE — Allergan Inc. said Tuesday it has quit distributing a marketing brochure for its anti-infection eye product, Ocuflox, after being cited by regulators for misleading customers about the product.
The Irvine-based drug company took that step after receiving a second notice from the Food and Drug Administration regarding marketing the product.
The notice, received earlier this month, was a follow-up to a May 30 letter in which the FDA said Allergan used data from test-tube experiments, rather than human tests, in promotional materials to suggest that Ocuflox kills more bacteria than competing products.
Jeff D’Eliscu, a company spokesman, said the company is having discussions with the FDA “on the proper way to present our data.” The company continues to sell the product, which has been on the market for nearly four years.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
